These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 9808413)

  • 21. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
    Iborra A; Mayorga M; Llobet N; Martínez P
    Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement regulatory proteins in the salivary glands and saliva of Sjögren's syndrome patients and healthy subjects.
    Cuida M; Legler DW; Eidsheim M; Jonsson R
    Clin Exp Rheumatol; 1997; 15(6):615-23. PubMed ID: 9444417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential expression of complement regulatory proteins decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 during human spermatogenesis.
    Simpson KL; Holmes CH
    Immunology; 1994 Mar; 81(3):452-61. PubMed ID: 7515850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of membrane-bound complement regulatory proteins in prostate cancer.
    Loberg RD; Wojno KJ; Day LL; Pienta KJ
    Urology; 2005 Dec; 66(6):1321-6. PubMed ID: 16360477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
    Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
    J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
    Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
    J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
    Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
    Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
    Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
    Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression of the complement regulators CD46, CD55, and CD59 by human sperm does not protect them from antisperm antibody- and complement-mediated immune injury.
    D'Cruz OJ; Haas GG
    Fertil Steril; 1993 Apr; 59(4):876-84. PubMed ID: 7681414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
    Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
    FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
    Ravindranath NM; Shuler C
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasms.
    Sayama K; Shiraishi S; Miki Y
    Br J Dermatol; 1992 Jul; 127(1):1-4. PubMed ID: 1379063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
    Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
    J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.